相关实验视频

Updated: May 30, 2025

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Published on: June 23, 2013

ALKBH5通过调节ITGB1脱甲基化和影响巨细胞极化来缓解下肢动脉硬化

Zeyu Guan¹, Xiaogao Wang¹, Chao Xu¹

¹The First Affiliated Hospital of Bengbu Medical University, Department of Vascular Surgery, 287 Changhuai Road, Bengbu, 233004, China.

|January 27, 2025

概括

在下肢动脉样硬化中增加的m6A甲基化与较低的ALKBH5水平有关. ALKBH5促进M2巨分化,通过去甲基化ITGB1来减少动脉样硬化,提供潜在的治疗点.

科学领域:

表观遗传学和心血管疾病
巨细胞生物学和动脉样硬化
动脉样硬化的分子机制

背景情况:

巨细胞的两极分化对于动脉样硬化发展至关重要.
在下肢动脉样硬化中N6-甲基氨酸 (m6A) 甲基化的特定作用及其对巨细胞两极分化的影响在很大程度上仍未被描述.
识别关键的监管因素对于理解和治疗这种疾病至关重要.

研究的目的:

研究m6A甲基化在下肢动脉样硬化中的作用.
在这种情况下,确定参与m6A介导的巨细胞两极分化的主要调节因素.
阐明这些因素影响动脉样硬化进展的潜在分子机制.

主要方法:

从患有下肢动脉样硬化的患者的外周血液单核细胞 (PBMC) 中评估m6A甲基化水平.
量化RNA甲基转移酶和脱甲基酶使用ELISA和西式涂抹.
利用细胞模型 (RAW264.7巨细胞) 和动脉样硬化小鼠模型 (ApoE-/-) 来检查ALKBH5及其标ITGB1的功能,包括巨细胞极化,斑块形成和基因稳定性.

主要成果:

在患有下肢动脉样硬化症的患者的PBMC中观察到m6A甲基化水平升高.
这些患者的RNA脱甲基酶ALKBH5的表达显著降低.
发现ALKBH5可以缓解下肢动脉硬化进展,并通过去甲基化减少ITGB1稳定性来促进M2巨分化.

结论:

ALKBH5通过促进M2巨细胞极化和减轻疾病进展,在下肢动脉样硬化中起着保护作用.
通过ALKBH5脱甲基化ITGB1是其动脉保护作用的关键机制.
这些发现突出了ALKBH5作为管理下肢动脉硬化的潜在治疗点.

关键词:

在 ALKBH5H5 中根据ITGB1的规定.下肢动脉动动脉样硬化下肢动脉动脉样硬化巨细胞的两极分化 m6A甲基化的情况.

更多相关视频

Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis

Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis

Published on: November 28, 2015

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...